Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.
PLoS One. 2013 Nov 8;8(11):e79719. doi: 10.1371/journal.pone.0079719. eCollection 2013.
The introduction of vaccination against Human Papillomavirus (HPV) in adolescent girls in 2006 has focused virological surveillance on this age group. As few studies have evaluated HPV infections in young populations, further data are needed in order to improve and extend prophylactic policy and to monitor epidemiological changes. The present study aimed at evaluating overall and type-specific HPV prevalence in both female and male adolescents in Italy. HPV DNA detection and genotyping was performed on urine samples collected from 870 unvaccinated adolescents (369 females, 501 males, 11-18 years of age) in five cities in Italy. Following DNA extraction by means of a commercial kit (NucliSENS(®)-miniMAG(®), bioMérieux), the L1 gene fragment was PCR amplified and genotyped by restriction fragment length polymorphism analysis. HPV DNA was detected in 1.5% of all samples, and in 3% and 0.4% of samples from females and males, respectively. In approximately 70% of HPV DNA positive adolescents, the infection was due to a single genotype, with 88.9% of genotypes belonging to the HR-clade. The only two HPV-positive boys (14 and 18 years old) had HPV-70 genotype. Only one of the 11 HPV-infected girls was in the 11-14 age-group. HPV prevalence was 4.2% in girls aged 15-18 years and 60% of infections were due to vaccine types HPV-16 or HPV-6/-11. This is one of the few studies, the first conducted in Italy, on HPV infection in adolescents. Urine testing is the easier way of detecting HPV infection in younger populations. Our data revealed a very low HPV prevalence, and no infections were observed in the 12-year-old vaccine target population. The majority of infections were seen in females aged 15-18 years. Overall, more than 50% and 30% of the potentially persistent HPV infections detected in this group could have been prevented by the quadrivalent and the bivalent vaccines, respectively.
2006 年在少女中引入 HPV 疫苗接种后,病毒学监测重点集中在该年龄组。由于很少有研究评估青少年人群中的 HPV 感染,因此需要进一步的数据来改善和扩大预防性政策,并监测流行病学变化。本研究旨在评估意大利青少年女性和男性的 HPV 总流行率和型特异性流行率。在意大利五个城市,从 870 名未接种疫苗的青少年(369 名女性,501 名男性,年龄 11-18 岁)的尿液样本中提取 HPV DNA 并进行基因分型。通过商业试剂盒(NucliSENS®-miniMAG®,bioMérieux)提取 DNA 后,通过聚合酶链反应扩增 L1 基因片段,并通过限制性片段长度多态性分析进行基因分型。在所有样本中,HPV DNA 的检出率为 1.5%,女性和男性样本中的检出率分别为 3%和 0.4%。在大约 70%的 HPV DNA 阳性青少年中,感染是由单一基因型引起的,其中 88.9%的基因型属于 HR 群。仅有的两名 HPV 阳性男孩(14 岁和 18 岁)的 HPV 基因型为 HPV-70。在 11 名 HPV 感染女孩中,只有 1 名年龄在 11-14 岁之间。15-18 岁女孩 HPV 流行率为 4.2%,感染的 60%是由 HPV-16 或 HPV-6/-11 疫苗型引起的。这是为数不多的研究之一,也是意大利首例青少年 HPV 感染研究。尿液检测是检测年轻人群 HPV 感染的一种较为简便的方法。我们的数据显示 HPV 流行率非常低,在目标年龄为 12 岁的人群中未观察到感染。感染主要发生在 15-18 岁的女性中。总体而言,在该组中检测到的潜在持续性 HPV 感染中,超过 50%和 30%可以分别通过四价和二价疫苗预防。